LONDON (Alliance News) – GlaxoSmithKline PLC said on Wednesday it will invest USD100 million in its manufacturing site in Montana, US, to expand long-term vaccine manufacturing capabilities.
In particular, the FTSE 100 pharmaceutical firm plans to expand the production capacity of key components of the adjuvant system, which is used for several of Glaxo’s vaccines for malaria and shingles.
“For more than a decade, our Hamilton facility has supported GSK’s adjuvant system development program. By expanding the adjuvant system production capabilities in Hamilton, we will continue to deliver long-term and sustainable supply for key vaccines, including Shingrix,” said Glaxo US Pharmaceuticals President Jack Bailey.
Shares in GlaxoSmithKline were down 0.9% at 1,543.40 pence on Wednesday afternoon.
25 April, 2019